FOXO4-DRI
Also known as: Proxofim, FOXO4-D-Retro-Inverso, FOXO4 p53 disruptor
FOXO4-DRI (also called Proxofim or FOXO4-D-Retro-Inverso) is a senolytic FOXO4 peptide. FOXO4-DRI is a retro-inverso peptide — built from D-amino acids in reversed sequence — modelled on the FOXO4 region that binds p53. In senescent cells FOXO4 sequesters p53 in the nucleus, preventing it from initiating apoptosis and allowing those cells to persist despite accumulated damage.
For research use only.
Key Facts
- CAS
- 2460055-10-9
- Molecular Weight (MW)
- 5358 g/mol
- Half-life
- Experimental; not established
- FDA status
- Not Approved
- Administration Route
- —
- Frequency
- —
- Last updated
- Aug 30, 2026
- Reviewed
- Aug 30, 2026
- Targets
- FOXO4–p53 interaction
Vendor price snapshot
Each vendor counts once, at the median price per mg of its own listings; the typical range is the middle half of vendors. From public vendor listings collected between Dec 2025 and Sep 2026, so confirm the live price on the vendor site. Peptide Library does not sell peptides.
- Vendors listing this peptide
- 10
- Listed offers
- 11
- Median price per mg
- $18.74/mg
- Typical $15.98–$24.50/mg
Research summary
D-retro-inverso peptide designed to disrupt FOXO4–p53 binding and clear senescent cells in mice (2017 Cell paper). No CAS as a registered drug; not FDA-approved. Often sold as Proxofim.
Peptide Library's FOXO4-DRI profile summarises 5 cited studies listed in the Science section, the compound's regulatory status, and research-protocol parameters reported for it. It is a research reference, not medical advice.
Protocol
- Dosage Range
- Not established (preclinical literature only)
- Frequency
- —
- Cycle
- —
- Administration Route
- —
- Reconstitution Guide
- —
Not yet checked against primary sources
These figures are compiled from earlier reference material. They have not been verified against FDA labelling, registered trials or published literature, no citation is attached to them, and none of them is a recommended dose. FOXO4-DRI is queued for dosage evidence review.
Compare reported doses across the whole librarySequence & molecular data
| Molecular formula | C228H388N86O64 |
|---|---|
| Molecular weight | 5358 g/mol |
| CAS number | 2460055-10-9 |
| Half-life | Experimental; not established |
| Appearance | Research peptide (sequence variants reported in literature) |
| Formulation | Lyophilized Powder |
| PubChem CID | 167312269 |
Identifiers link to the public PubChem, FDA Substance Registration (UNII), ChEMBL and DrugBank records for the same entity.
Science
Mechanism of Action
FOXO4-DRI is a retro-inverso peptide — built from D-amino acids in reversed sequence — modelled on the FOXO4 region that binds p53. In senescent cells FOXO4 sequesters p53 in the nucleus, preventing it from initiating apoptosis and allowing those cells to persist despite accumulated damage. The peptide competes for that interaction, releasing p53 to translocate to the mitochondria and trigger apoptosis. Because the FOXO4-p53 interaction is markedly more important in senescent than in healthy cells, the effect is relatively selective for senescent fibroblasts, which is what makes it a senolytic. The retro-inverso construction confers protease resistance. Evidence comes from the original mouse work; there are no human trials.
Origin
Synthetic D-retro-inverso peptide (Baar et al., Cell 2017).
Targets
Studies
- The disordered p53 transactivation domain is the target of FOXO4 and the senolytic compound FOXO4-DRI
- FOXO4-DRI regulates endothelial cell senescence via the P53 signaling pathway
- FOXO4-DRI induces keloid senescent fibroblast apoptosis by promoting nuclear exclusion of upregulated p53-serine 15 phosphorylation
- FOXO4-DRI improves spermatogenesis in aged mice through reducing senescence-associated secretory phenotype secretion from Leydig cells
- FOXO4-D-Retro-Inverso targets extracellular matrix production in fibroblasts and ameliorates bleomycin-induced pulmonary fibrosis in mice
Regulatory & research status
FOXO4-DRI is not an FDA-approved product. It is sold for laboratory research and has no approved medical use.
| FDA status | Not Approved |
|---|---|
| Availability | Research-Only |
| WADA (sport) | Banned in Sport |
| Library classification | Research-Only |
Benefits
FOXO4-DRI side effects
Side Effects
- No established human dose
- On-target p53 risks theoretical
Storage & stability
Lyophilized (freeze-dried) peptide powder is far more stable than the reconstituted solution. Keep sealed vials cold, dry and away from light; long-term storage is typically frozen, with short-term refrigeration for vials in use.
Once reconstituted in bacteriostatic water, keep the solution refrigerated, avoid repeated freeze–thaw cycles and agitation, and label the vial with the reconstitution date and concentration. Discard any solution that turns cloudy or shows particulates.
Degradation rates differ by sequence: peptides containing methionine, cysteine, asparagine or glutamine are more prone to oxidation and deamidation, so shelf life after reconstitution is compound-specific rather than universal.
Read the full guide: how to store peptides before and after reconstitution →
Source: Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. Stability of protein pharmaceuticals: an update. Pharm Res. 2010;27(4):544–575. (PMID 20143256). General guidance for research handling; not product-specific instructions.
FOXO4-DRI: frequently asked questions
What is FOXO4-DRI?
D-retro-inverso peptide designed to disrupt FOXO4–p53 binding and clear senescent cells in mice (2017 Cell paper). No CAS as a registered drug; not FDA-approved. Often sold as Proxofim.
How does FOXO4-DRI work?
FOXO4-DRI is a retro-inverso peptide — built from D-amino acids in reversed sequence — modelled on the FOXO4 region that binds p53. In senescent cells FOXO4 sequesters p53 in the nucleus, preventing it from initiating apoptosis and allowing those cells to persist despite accumulated damage.
Is FOXO4-DRI FDA approved?
No. FOXO4-DRI is not approved by the FDA for any indication and is categorised as research-only. It has not been reviewed for safety or efficacy as a medicine, and published research should be read as investigation rather than established use.
What is the half-life of FOXO4-DRI?
Reported half-life for FOXO4-DRI is Experimental; not established. Half-life describes how long the compound persists in circulation, not how long any effect lasts, and published figures vary with route of administration, formulation and the population studied.
Is FOXO4-DRI banned in sport?
FOXO4-DRI is recorded here as prohibited in sport. Athletes subject to anti-doping rules should check the current WADA Prohibited List directly, since it is revised annually and classifications change.
What peptides are similar to FOXO4-DRI?
Compounds most often compared with FOXO4-DRI include Epitalon, Pinealon, Klotho and NAD+ (Nicotinamide Adenine Dinucleotide). They are grouped by shared mechanism or research area rather than by equivalence, and their regulatory status and evidence base differ.
References
- The disordered p53 transactivation domain is the target of FOXO4 and the senolytic compound FOXO4-DRI — Nat Commun, 2025External reference
- FOXO4-DRI regulates endothelial cell senescence via the P53 signaling pathway — Front Bioeng Biotechnol, 2025External reference
- FOXO4-DRI induces keloid senescent fibroblast apoptosis by promoting nuclear exclusion of upregulated p53-serine 15 phosphorylation — Commun Biol, 2025External reference
- FOXO4-DRI improves spermatogenesis in aged mice through reducing senescence-associated secretory phenotype secretion from Leydig cells — Exp Gerontol, 2024External reference
- FOXO4-D-Retro-Inverso targets extracellular matrix production in fibroblasts and ameliorates bleomycin-induced pulmonary fibrosis in mice — Naunyn Schmiedebergs Arch Pharmacol, 2023External reference
Related research, comparisons & guides
Related peptides
Compiled by Peptide Library Editorial · Reviewed Aug 30, 2026 · Updated Aug 30, 2026 · Version 1
This FOXO4-DRI profile is compiled from published literature (5 cited studies linked above), public regulatory records and chemical registries. It describes what research reports; it is not medical advice, and nothing here is a dosing recommendation for humans. Peptide Library does not sell peptides. Editorial policy · How profiles are compiled · Report an error
Track FOXO4-DRI research, inventory and reconstitution in the free Peptide Library app. Get the app for iOS or Android →